Replies to post #245400 on Biotech Values

[dewophile]

There is a real unmet need here bc of the very high bleeding risk if you have someone who needs an antiplatelet agent for say TIA/stroke due to plaque who also needs to stay on a drug like eliquis for afib. Downstream effects would not just be to take share from Xa inhibitors, but also result in a mild negative for companies like BSX which sell devices like the watchman

[iwfal]

Bayer’s competition in this arena (Factor XI, XIa) is BMY/JNJ’s Milvexian

FWIW the leader is Anthos Therapeutics, a private company, with Abelacimab. The whole saga is interesting because I tried to invest almost a decade ago, but Ionis is a disaster of mismanagement (see note below on Ionis). And a disaster for patients because for a LONG time the experts derided the whole concept of immensely lower bleeding risk for some important classes of clot prevention.

https://www.prnewswire.com/news-releases/abelacimab-first-factor-xi-inhibitor-to-enroll-patients-in-a-phase-3-clinical-trial-301541160.html

Regarding Ionis: recently heard former Ionis CEO Stanley Crooke on a podcast and he was surprisingly forthright. He intentionally torched any attempts to make product revenue because he strongly believes it destroys science.